Population
Transgenic mouse model of myotonic dystrophy
Design
Preclinical
Authors
Loading...
CAG25 reverses molecular defects in a myotonic dystrophy mouse model; leaves open whether antisense oligonucleotides will prove safe or effective in patients.
Antisense oligonucleotides can reverse the molecular and functional derangements of myotonic dystrophy in a transgenic mouse model by blocking pathogenic RNA-protein interactions.
Wheeler et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: